Global artificial intelligence (AI) in drug discovery market will reach $2.57 billion by 2026, growing by 30.3% annually over 2020-2026 despite the COVID-19 impact.
Highlighted with 86 tables and 86 figures, this 178-page report “Global Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global AI in drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report provides historical market data for 2015-2019, revenue estimates for 2020, and forecasts from 2021 till 2026.

Get HOLISTIC Request Sample of This Business Report:
https://axelreports.com/request-sample/105434

In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global AI in drug discovery market in every aspect of the classification from perspectives of Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Region.
Based on offering, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Software
• Service
Based on technology, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Deep Learning
• Supervised Learning
• Reinforcement Learning
• Unsupervised Learning
• Other Technologies
Based on drug type, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Large-molecule Drugs
• Small-molecular Drugs
Based on therapeutic area, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Oncology
• Neurodegenerative Diseases
• Cardiovascular Disease
• Metabolic Diseases
• Other Therapeutic Areas
Based on application, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Information & Data Analysis
• Drug Design
• Drug Evaluation
• Clinical Trials
• Other Applications
Based on end user, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations
Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• RoW (Saudi Arabia, UAE, Egypt)
For each of the aforementioned regions and countries, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of all regional markets by country and split of key national markets by Technology, Therapeutic Area, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global AI in drug discovery market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Get HOLISTIC Request Customization of This Business Report:
https://axelreports.com/request-customization/105434

Key Players (this may not be a complete list and extra companies can be added upon request):
• Atomwise, Inc.
• BenevolentAI
• Berg LLC
• Bioage
• BIOAGE
• Cloud Pharmaceuticals, Inc.
• Cyclica
• Deep Genomics
• Envisagenics
• Exscientia
• Google
• IBM Corporation
• Insilico Medicine
• Microsoft Corporation
• Numedii, Inc.
• Numerate
• NVIDIA Corporation
• Owkin, Inc.
• Twoxar, Incorporated
• Verge Genomics
• Xtalpi, Inc.

Axel Reports
US Office
30 BEAVER ST. WORCESTER, MASSACHUSETTS 01603, UNITED STATES
India Office
Office No. P-221, Marvel Sangria Boulevard N.I.B.M. Road Pune -411060
India +18488639402
[email protected]
[email protected]